Nothing Special   »   [go: up one dir, main page]

Fletcher et al., 1995 - Google Patents

Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist

Fletcher et al., 1995

View PDF
Document ID
9367461406908488054
Author
Fletcher A
Forster E
Bill D
Brown G
Cliffe I
Hartley J
Jones D
McLenachan A
Stanhope K
Critchley D
Childs K
Middlefell V
Lanfumey L
Corradetti R
Laporte A
Gozlan H
Hamon M
Dourish C
Publication year
Publication venue
Behavioural brain research

External Links

Snippet

Although considerable progress has been made in characterising the 5-HT1A receptor using agonists, partial agonists or non-selective antagonists, further studies of 5-HT1A receptor function have been hindered by the lack of highly selective antagonists. The term …
Continue reading at www.academia.edu (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Similar Documents

Publication Publication Date Title
Fletcher et al. Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist
Amargós-Bosch et al. Co-expression and in vivo interaction of serotonin1A and serotonin2A receptors in pyramidal neurons of prefrontal cortex
Aznavour et al. [18F] MPPF as a tool for the in vivo imaging of 5-HT1A receptors in animal and human brain
Gozlan et al. The selective 5-HT1A antagonist radioligand [3H] WAY 100635 labels both G-protein-coupled and free 5-HT1A receptors in rat brain membranes
Forster et al. A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635
Waddington et al. The D-1 dopamine receptor and the search for its functional role: from neurochemistry to behaviour
MAITRE The γ-hydroxybutyrate signalling system in brain: organization and functional implications
Meneses Physiological, pathophysiological and therapeutic roles of 5-HT systems in learning and memory
Laporte et al. Selective in vivo labelling of brain 5-HT1A receptors by [3H] WAY 100635 in the mouse
Le Poul et al. Differential adaptation of brain 5-HT1A and 5-HT1B receptors and 5-HT transporter in rats treated chronically with fluoxetine
Sakurai et al. Regional distribution and properties of [3H] MK-801 binding sites determined by quantitative autoradiography in rat brain
Castelli et al. Selective γ‐hydroxybutyric acid receptor ligands increase extracellular glutamate in the hippocampus, but fail to activate G protein and to produce the sedative/hypnotic effect of γ‐hydroxybutyric acid
Le Foll et al. Dopamine D3 receptor ligands for drug addiction treatment: update on recent findings
CA2546147A1 (en) Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof
Corradetti et al. Antagonist properties of (−)‐pindolol and WAY 100635 at somatodendritic and postsynaptic 5‐HT1A receptors in the rat brain
Jolas et al. (−) Tertatolol is a potent antagonist at pre-and postsynaptic serotonin 5-HT 1A receptors in the rat brain
CN109745316A (en) Combination therapy for treating cancer
BR112015026292B1 (en) USE OF 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOLE-3-YL)PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO [2,3-B]PYRAZIN -2(1H)- ONA AND IN VITRO METHODS
Thomas et al. SB-699551-A (3-cyclopentyl-N-[2-(dimethylamino) ethyl]-N-[(4′-{[(2-phenylethyl) amino] methyl}-4-biphenylyl) methyl] propanamide dihydrochloride), a novel 5-ht5A receptor-selective antagonist, enhances 5-HT neuronal function: evidence for an autoreceptor role for the 5-ht5A receptor in guinea pig brain
Oi et al. Development of novel PET probes for central 2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl) propionic acid receptors
Kung et al. In vivo binding of [123I] 4‐(2′‐methoxy phenyl)‐1‐[2′‐(N‐2 ″‐pyridinyl)‐P‐iodobenzamido‐] ethyl‐piperazine, p‐MPPI, to 5‐HT1A receptors in rat brain
Tilakaratne et al. Genomic responses to 5-HT1a or 5-HT2a2c receptor activation is differentially regulated in four regions of rat brain
Ginovart et al. In vivo characterization of p‐[18F] MPPF, a fluoro analog of WAY‐100635 for visualization of 5‐HT1a receptors
Ogawa et al. Pharmacological profiles of R-96544, the active form of a novel 5-HT2A receptor antagonist R-102444
Zhang et al. Trapping of nicotinic acetylcholine receptor ligands assayed by in vitro cellular studies and in vivo PET imaging